Wolfe Research initiated coverage of Definium Therapeutics (DFTX) with an Outperform rating and $25 price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas.” Wolfe names Definium its top pick for psychedelics, which is one of its favorite central nervous system areas. It sees the stock moving up in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DFTX:
- Psychedelic: Exclusive talk with nonprofit organization MAPS
- Psychedelic: Analyst initiates Definium, Helus with Buy ratings
- Spotify upgraded, Pinterest downgraded: Wall Street’s top analyst calls
- Definium Therapeutics initiated with a Buy at Jefferies
- Psychedelic: Analyst raises Compass, Definium, GH Research price targets